NSCLC EA5163

Study #EA5163

INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone of in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunoblocker SIGNature-Driven Analysis